Forte Biosciences, Inc. (FBRX)
About Forte Biosciences, Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2019
- $36.0K
- Net income
- -$69.4M
- Total assets
- $82.8M
- Market cap
- $338.3M
- Operating margin
- -2602.5%
- Net margin
- -2555.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.7M
- Operating expenses
- $70.7M
- Operating income
- -$70.7M
- Income tax
- $1.0M
- Net income
- -$69.4M
- EPS (basic)
- $-4.71
- EPS (diluted)
- $-4.71
Balance sheet
- Total assets
- $82.8M
- Current assets
- $80.6M
- Total liabilities
- $21.8M
- Current liabilities
- $20.8M
- Shareholders’ equity
- $61.0M
Cash flow
- Operating cash flow
- -$50.9M
- Investing cash flow
- $36.2M
- Financing cash flow
- $69.4M
- Net cash flow
- $54.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $338.3M
- EPS (diluted)
- $-4.71
- Shares outstanding
- 6.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 16, 2020
Forte Biosciences, Inc. (FBRX) Stock Price
- Reported a net loss of $69.4M in FY2019.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Forte Biosciences, Inc..
Write a review
News about Forte Biosciences, Inc.
News & sentiment via Polygon.io
Forte Biosciences, Inc.: frequently asked questions
Is Forte Biosciences, Inc. an American company?
Forte Biosciences, Inc. is a US-based company headquartered in Dallas, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Forte Biosciences, Inc. headquartered?
Forte Biosciences, Inc. is headquartered in Dallas, Texas, United States.
Is Forte Biosciences, Inc. publicly traded?
Yes — Forte Biosciences, Inc. is a publicly traded company. Its stock trades under the ticker symbol FBRX on the NASDAQ.
What does Forte Biosciences, Inc. do?
Forte Biosciences, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
